NEKTAR THERAPEUTICS — Director's Dealing 2019

Dec 5, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2019-12-02

Reporting Person: NORTHCOTT JOHN (SVP & Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-12-02	Common Stock	A	200000	$0.00	Acquired	200000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-12-02	Stock Option	$19.48	A	200000	Acquired	2027-12-01	Common Stock (200000)	Direct

Footnotes

F1: The grant of Restricted Stock Units ("RSUs") will vest according to a four-year vesting schedule, with 25% vesting on February 15, 2021 and the remainder vesting over three years in equal quarterly installments.

F2: This option vests as to 25% of the shares subject to the option on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest in equal monthly installments over the three-year period thereafter, in each case based on the Reporting Person's continuous service to the issuer.